

No.	K22-3063	
研究課題名	Human Systems Immunology of vaccine and immunotherapy	
研究代表者	Katsikis Peter (Erasmus University Medical Center ・教授)	
研究組織	受入教員	石井 健 (東京大学医科学研究所 ・教授)
	分担者	Ken Ishii ((2) Division of Vaccine Science, Department of Microbiology and Immunology, International Vaccine Design Center (vDesC) ・Professor)

IMSUT International Joint Usage/Research Center Project <International>**Joint Research Report (Annual/Project Completion)**

Annual Report			
Report			
Project Members			
Name	Institution/ Department	Title	Role
Peter Katsikis		Professor	Leading the project
Melisa D. Castro Eiro	Erasmus MC, University Medical Center/ Dep. of Immunology	Postdoc fellow	Conducting the exp
Kou Hioki		Postdoc fellow	Conducting the exp
Quentin Sattentau		Oxford University/ SWD school of pathology	Professor
Ken Ishii	U Tokyo/ IMS, Dep. Infection and Immunology	Professor	Co-leading the proj.
Kouji Kobiyama		Assoc. Prof.	Conducting the exp
Hideo Negishi		Senior Assist.Prof.	Conducting the exp
Burcu Temizoz		Assist. Prof.	Conducting the exp
Tomoya Hayashi		Postdoc. Fellow	Conducting the exp
Etsushi Kuroda	Hyogo College of Medicine, Dep. Immunology	Professor	Co-leading the proj.

Research Progress Report

Current collaborative research focusing on the systems immunology for developing better vaccines and immunotherapies led to various findings, especially about the modes of action of novel vaccine adjuvant combinations as not only vaccine adjuvants but also as cancer immunotherapeutics. In the Peter Katsikis's lab, by using our original adjuvant K3-SPG along with the additional adjuvants sent from Ken Ishii lab, they found that some adjuvants show robust anti-tumor effect, especially when used in combination. They are further conducting these cancer immunotherapy studies in mice to find out the mechanisms of action of those adjuvants. Moreover, based on our discussions about their and our scientific findings about the anti-tumor effect of those adjuvants, we are exploring ways to make reagents GMP quality and perform toxicity testing in order to be able to proceed to clinical trials.

In the Ken Ishii's Lab, studies by Temizoz et al. showed that TLR9 and STING agonists can synergistically induce anti-tumor immunity in mice via the mechanisms regulated at the transcriptional levels. Our further clinical studies by using the TLR9 agonist CpG ODN in the lung cancer patients revealed that CpG ODN can trigger Th1-type immune response and enhance cytotoxic activity in advanced lung cancer patients. Moreover, another phase 1 clinical trial showed that hydroxypropyl- β -cyclodextrin shows adjuvant activity by enhancing the immunogenicity of the quadrivalent seasonal influenza vaccine without significant side effects.

Nevertheless, this collaboration led to the finding that potent T cell immunity against tumor neoantigens could be elicited by adjuvant combinations. Studies using neoantigen vaccination SQ have shown potent T cell immunity and protection against subcutaneous melanoma tumors. Initial experiments have suggested that intra-

tumor vaccination augments any protective effect of SQ vaccination but also shows promise when intra-tumor vaccination is used alone. Such intra-tumor vaccinations result in large tumor necrosis and delay in tumor growth. Continuation of these studies will examine the extent of protection in 3 different tumor models (melanoma, mesothelioma and pancreatic cancer).

The manuscript below describing the adjuvant combination used together with neoantigen synthetic long peptides has been submitted:

Melisa D. Castro Eiro, Kou Hioki, Ling Li, Merel Wilmsen, Caoimhe H. Kiernan, IngeBrouwers–Haspels, Marjan van Meurs, Manzhi Zhao, Harm de Wit, Dwin G. B. Grashof, Harmen J. G. van de Werken, Yvonne M. Mueller, Christopher Schliehe, **Burcu Temizoz, Kouji Kobiyama, Ken J. Ishii, Peter D. Katsikis**: “TLR9 plus STING agonist adjuvant combination induces potent neopeptide T cell immunity and improves immune checkpoint blockade efficacy in tumor models” (In Revision).

Peter D. Katsikis, Ken J. Ishii, Christopher Schliehe: “Challenges in developing personalized neoantigen cancer vaccines” (Submitted)

By using a machine learning-assisted screening on the herbal medicine extracts that could potentially have adjuvant activity, Hioki et al. found novel parameters, such as human G-CSF and mouse RANTES, that could be used as adjuvanticity biomarkers for adjuvant screening by using the data obtained from in vitro human studies and in vitro and in vivo mice studies. Moreover, Yoshioka et al.’s studies in Ken Ishii’s lab demonstrated that the novel adjuvant A-910823 is capable of robustly inducing Tfh cell and humoral immune responses, even when used as a booster dose. And the adjuvant activity of A-910823 was dependent on α -tocopherol component of this novel adjuvant.

Therefore, we believe that our studies may lead to identification of novel adjuvants or biomarkers that could be used to measure adjuvanticity, as well as mode of action of adjuvants both in human and mice, which could subsequently aid in development of better vaccines or immunotherapies for human.

Published Papers

Yoshioka Y, **Kobiyama K**, Hayashi T, Onishi M, Yanagida Y, Nakagawa T, Hashimoto M, Nishinaka A, Hirose J, Asaoka Y, Tajiri M, Hayata A, Ishida S, Omoto S, Nagira M, **Ishii KJ**. A-910823, a squalene-based emulsion adjuvant, induces T follicular helper cells and humoral immune responses via α -tocopherol component. *Front Immunol.* 2023 Feb 20;14:1116238. doi: 10.3389/fimmu.2023.1116238. PMID: 36891311; PMCID: PMC9986537.

Kawasaki T, Ikegawa M, Yunoki K, Otani H, Ori D, **Ishii KJ, Kuroda E**, Takamura S, Kitabatake M, Ito T, Isoni A, Kawai T. Alveolar macrophages instruct CD8+ T cell expansion by antigen cross-presentation in lung. *Cell Rep.* 2022 Dec 13;41(11):111828. doi: 10.1016/j.celrep.2022.111828.

Orecchioni M, Wolf D, Suryawanshi V, Winkels H, **Kobiyama K**, Makings J, Kiosses WB, Ley K. Deleting interleukin-10 from myeloid cells exacerbates atherosclerosis in Apoe^{-/-} mice. *Cell Mol Life Sci.* 2022 Dec 10;80(1):10. doi: 10.1007/s00018-022-04649-9.

Otsubo R, Minamitani T, **Kobiyama K**, Fujita J, Ito T, Ueno S, Anzai I, Tanino H, Aoyama H, Matsuura Y, Namba K, Imadome KI, **Ishii KJ**, Tsumoto K, Kamitani W, Yasui T. Human antibody recognition and neutralization mode on the NTD and RBD domains of SARS-CoV-2 spike protein. *Sci Rep.* 2022 Nov 22;12(1):20120. doi: 10.1038/s41598-022-24730-4.

Kimura I, Yamasoba D, Tamura T, Nao N, Suzuki T, Oda Y, Mitoma S, Ito J, Nasser H, Zahradnik J, Uriu K, Fujita S, Kosugi Y, Wang L, Tsuda M, Kishimoto M, Ito H, Suzuki R, Shimizu R, Begum MM, Yoshimatsu K, Kimura KT, Sasaki J, Sasaki-Tabata K, Yamamoto Y, Nagamoto T, Kanamune J, **Kobiyama K**, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Shirakawa K, Takaori-Kondo A, Kuramochi J, Schreiber G, **Ishii KJ**; Genotype to Phenotype Japan (G2P-Japan) Consortium; Hashiguchi T, Ikeda T, Saito A, Fukuhara T, Tanaka S, Matsuno K, Sato K. Virological characteristics of the SARS-CoV-2 Omicron BA.2 subvariants, including BA.4 and BA.5. *Cell.* 2022 Oct 13;185(21):3992-4007.e16. doi: 10.1016/j.cell.2022.09.018.

Nomura Y, Noda K, Oohashi Y, Okuda S, Matsumoto J, Nakano T, **Tsuchida N, Ishii KJ**, Hayashi K, Iiyama T, Onodera H, Ishii K, Shikano M, Okabe N. Proposal for the revision of guidelines for clinical trials of vaccines to prevent infectious diseases in Japan. *Vaccine.* 2022 Oct 12;40(43):6295-6304. doi: 10.1016/j.vaccine.2022.09.036.

Matsuda T, Misato K, Tamiya S, Akeda Y, Nakase I, **Kuroda E**, Takahama S, Nonaka M, Yamamoto T, Fukuda MN, Yoshioka Y. Efficient antigen delivery by dendritic cell-targeting peptide via nucleolin confers superior vaccine effects in mice. *iScience.* 2022 Oct 10;25(11):105324. doi:

10.1016/j.isci.2022.105324. PMID: 36304121; PMCID: PMC9593262.

Washizaki A, Murayama A, Murata M, Kiyohara T, Yato K, Yamada N, Aly HH, Tanaka T, Moriishi K, Nishitsuji H, Shimotohno K, Goh Y, **Ishii KJ**, Yotsuyanagi H, Muramatsu M, Ishii K, Takahashi Y, Suzuki R, Akari H, Kato T. Neutralization of hepatitis B virus with vaccine-escape mutations by hepatitis B vaccine with large-HBs antigen. *Nat Commun.* 2022 Sep 5;13(1):5207. doi: 10.1038/s41467-022-32910-z.

Otsuka T, Nishida S, Shibahara T, **Temizoz B**, Hamaguchi M, Shiroyama T, Kimura K, Miyake K, Hirata H, Mizuno Y, Yagita M, Manabe Y, **Kuroda E**, Takeda Y, Kida H, **Ishii KJ**, Kumanogoh A. CpG ODN (K3)-toll-like receptor 9 agonist-induces Th1-type immune response and enhances cytotoxic activity in advanced lung cancer patients: a phase I study. *BMC Cancer.* 2022 Jul 7;22(1):744. doi: 10.1186/s12885-022-09818-4. PMID: 35799134; PMCID: PMC9264631.

Temizoz B, **Hioki K**, Kobari S, Jounai N, Kusakabe T, Lee MSJ, Coban C, **Kuroda E**, **Ishii KJ**. Anti-tumor immunity by transcriptional synergy between TLR9 and STING activation. *Int Immunol.* 2022 Jul 4;34(7):353-364. doi: 10.1093/intimm/dxac012. PMID: 35419609.

Yamada S, Kitai Y, Tadokoro T, Takahashi R, Shoji H, Maemoto T, Ishiura M, Muromoto R, Kashiwakura JI, **Ishii KJ**, Maenaka K, Kawai T, Matsuda T. Identification of RPL15 60S Ribosomal Protein as a Novel Topotecan Target Protein That Correlates with DAMP Secretion and Antitumor Immune Activation. *J Immunol.* 2022 Jul 1;209(1):171-179. doi: 10.4049/jimmunol.2100963.

Yamasoba D, Kimura I, Nasser H, Morioka Y, Nao N, Ito J, Uriu K, Tsuda M, Zahradnik J, Shirakawa K, Suzuki R, Kishimoto M, Kosugi Y, **Kobiyama K**, Hara T, Toyoda M, Tanaka YL, Butlertanaka EP, Shimizu R, Ito H, Wang L, Oda Y, Orba Y, Sasaki M, Nagata K, Yoshimatsu K, Asakura H, Nagashima M, Sadamasu K, Yoshimura K, Kuramochi J, Seki M, Fujiki R, Kaneda A, Shimada T, Nakada TA, Sakao S, Suzuki T, Ueno T, Takaori-Kondo A, **Ishii KJ**, Schreiber G; Genotype to Phenotype Japan (G2P-Japan) Consortium; Sawa H, Saito A, Irie T, Tanaka S, Matsuno K, Fukuhara T, Ikeda T, Sato K. Virological characteristics of the SARS-CoV-2 Omicron BA.2 spike. *Cell.* 2022 Jun 9;185(12):2103-2115.e19. doi: 10.1016/j.cell.2022.04.035.

Watanabe A, Nishida S, **Burcu T**, Shibahara T, Kusakabe T, **Kuroda E**, **Ishii KJ**, Kumanogoh A. Safety and immunogenicity of a quadrivalent seasonal influenza vaccine adjuvanted with hydroxypropyl- β -cyclodextrin: A phase 1 clinical trial. *Vaccine.* 2022 Jul 29;40(31):4150-4159. doi: 10.1016/j.vaccine.2022.05.060. Epub 2022 Jun 4. PMID: 35672178.

Hioki K, **Hayashi T**, Natsume-Kitatani Y, **Kobiyama K**, **Temizoz B**, **Negishi H**, Kawakami H, Fuchino H, **Kuroda E**, Coban C, Kawahara N, **Ishii KJ**. Machine Learning-Assisted Screening of Herbal Medicine Extracts as Vaccine Adjuvants. *Front Immunol.* 2022 May 19;13:847616. doi: 10.3389/fimmu.2022.847616. PMID: 35663999; PMCID: PMC9160479.

Nomura Y, Noda K, Oohashi Y, Okuda S, Maki K, Ogawa T, Nakano T, Tsuchida N, **Ishii KJ**, Hayashi K, Iiyama T, Onodera H, Ishii K, Shikano M, Okabe N. Proposal for the revision of the guidelines for Non-clinical studies of vaccines for the prevention of infectious diseases in Japan. *Vaccine.* 2022 Apr 26;40(19):2810-2818. doi: 10.1016/j.vaccine.2022.03.043.

Kobiyama K, **Ishii KJ**. Making innate sense of mRNA vaccine adjuvanticity. *Nat Immunol.* 2022 Apr;23(4):474-476. doi: 10.1038/s41590-022-01168-4.

Jongkees MJ, Geers D, Hensley KS, Huisman W, GeurtsvanKessel CH, Bogers S, Gommers L, Papageorgiou G, Jochems SP, den Hollander JG, Schippers EF, Ammerlaan HSM, Bierman WFW, van der Valk M, Berrevoets MAH, Soetekouw R, Langebeek N, Bruns AHW, Leyten EMS, Sigaloff KCE, van Vonderen MGA, Delsing CE, Branger J, **Katsikis PD**, Mueller YM, de Vries RD, Rijnders BJA, Brinkman K, Rokx C, Roukens AHE. Immunogenicity of an additional mRNA-1273 SARS-CoV-2 vaccination in people with HIV with hyporesponse after primary vaccination. *J Infect Dis.* 2022 Nov 19;jiac451. doi: 10.1093/infdis/jiac451. PMID: 36402141

Kumova OK, Galani IE, Rao A, Johnson H, Triantafyllia V, Matt SM, Pascasio J, Gaskill PJ, Andreacos E, **Katsikis PD**, Carey AJ. Severity of neonatal influenza infection is driven by type I interferon and oxidative stress. *Mucosal Immunol.* 2022 Jun;15(6):1309-1320. doi: 10.1038/s41385-022-00576-x. Epub 2022 Nov 9. PMID: 36352099

Hensley KS, Jongkees MJ, Geers D, GeurtsvanKessel CH, Mueller YM, Dalm VASH, Papageorgiou G, Steggink H, Gorska A, Bogers S, den Hollander JG, Bierman WFW, Gelinck LBS, Schippers EF, Ammerlaan HSM, van der Valk M, van Vonderen MGA, Delsing CE, Gisolf EH, Bruns AHW, Lauw FN, Berrevoets MAH, Sigaloff KCE, Soetekouw R, Branger J, de Mast Q, Lammers AJJ, Lowe SH, de Vries

RD, **Katsikis PD**, Rijnders BJA, Brinkman K, Roukens AHE, Rokx C. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines in people living with HIV in the Netherlands: A nationwide prospective cohort study. *PLoS Med.* 2022 Oct 27;19(10):e1003979. doi: 10.1371/journal.pmed.1003979. PMID: 36301821; PMCID: PMC9612532

Kaiser FMP, Gruenbacher S, Oyaga MR, Nio E, Jaritz M, Sun Q, van der Zwaag W, Kreidl E, Zopf LM, Dalm VASH, Pel J, Gaiser C, van der Vliet R, Wahl L, Rietman A, Hill L, Leca I, Driessen G, Laffeber C, Brooks A, **Katsikis PD**, Lebbink JHG, Tachibana K, van der Burg M, De Zeeuw CI, Badura A, Busslinger M. Biallelic PAX5 mutations cause hypogammaglobulinemia, sensorimotor deficits, and autism spectrum disorder. *J Exp Med.* 2022 Sep 5;219(9):e20220498. doi: 10.1084/jem.20220498. Epub 2022 Aug 10. PMID: 35947077; PMCID: PMC9372349.

Zguro K, Baldassarri M, Fava F, Beligni G, Daga S, Leoncini R, Galasso L, Cirianni M, Rusconi S, Siano M, Francisci D, Schiaroli E, Luchi S, Morelli G, Martinelli E, Girardis M, Busani S, Parisi SG, Panese S, Piscopo C, Capasso M, Tacconi D, Spertilli Raffaelli C, Giliberti A, Gori G, **Katsikis PD**, Lorubbio M, Calzoni P, Ognibene A, Bocchia M, Tozzi M, Bucalossi A, Marotta G, Furini S, Gen-Covid Multicenter Study, Renieri A, Fallerini C. Carriers of ADAMTS13 Rare Variants Are at High Risk of LifeThreatening COVID-19. *Viruses.* 2022 May 29;14(6):1185. doi: 10.3390/v14061185. PMID: 35746657; PMCID: PMC9227269.

Petkau G, Mitchell TJ, Chakraborty K, Bell SE, D Angeli V, Matheson L, Turner DJ, Saveliev A, Gizlenci O, Salerno F, **Katsikis PD**, Turner M. The timing of differentiation and potency of CD8 effector function is set by RNA binding proteins. *Nat Commun.* 2022 Apr 27;13(1):2274. doi: 10.1038/s41467-022-29979-x. PMID: 35477960; PMCID: PMC9046422.

Mueller YM, Schrama TJ, Ruijten R, Schreurs MWJ, Grashof DGB, van de Werken HJG, Lasinio GJ, Álvarez-Sierra D, Kiernan CH, Castro Eiro MD, van Meurs M, Brouwers-Haspels I, Zhao M, Li L, de Wit H, Ouzounis CA, Wilmsen MEP, Alofs TM, Laport DA, van Wees T, Kraker G, Jaimes MC, Van Bockstael S, Hernández-González M, Rokx C, Rijnders BJA, Pujol-Borrell R, **Katsikis PD**. Stratification of hospitalized COVID-19 patients into clinical severity progression groups by immuno-phenotyping and machine learning. *Nat Commun.* 2022 Feb 17;13(1):915. doi: 10.1038/s41467-022-28621-0. PMID: 35177626

Hope JL, Zhao M, Stairiker CJ, Kiernan CH, Carey AJ, Mueller YM, van Meurs M, Brouwers-Haspels I, Otero DC, Bae EA, Faso HA, Maas A, de Looper H, Fortina PM, Rigoutsos I, Bradley LM, Erkeland SJ, **Katsikis PD**. MicroRNA-139 Expression Is Dispensable for the Generation of Influenza-Specific CD8+ T Cell Responses. *J Immunol.* 2022 Feb 1;208(3):603-617. doi: 10.4049/jimmunol.2000621. Epub 2022 Jan 12. PMID: 35022277

Deimel LP, Liu X, Gilbert-Jaramillo J, Liu S, James WS, **Sattentau QJ**. Intranasal SARS-CoV-2 spikebased immunisation adjuvanted with polyethyleneimine elicits mucosal and systemic humoral responses in mice. *J Immunol Methods.* 2022 Oct 25;511:113380. doi: 10.1016/j.jim.2022.113380. Epub ahead of print. PMID: 36306825; PMCID: PMC9597555.

Buchanan CJ, Gaunt B, Harrison PJ, Yang Y, Liu J, Khan A, Giltrap AM, Le Bas A, Ward PN, Gupta K, Dumoux M, Tan TK, Schimaski L, Daga S, Picchiotti N, Baldassarri M, Benetti E, Fallerini C, Fava F, Giliberti A, Koukos PI, Davy MJ, Lakshminarayanan A, Xue X, Papadakis G, Deimel LP, Casablanco Antràs V, Claridge TDW, Bonvin AMJJ, **Sattentau QJ**, Furini S, Gori M, Huo J, Owens RJ, Schaffitzel C, Berger I, Renieri A; GEN-COVID Multicenter Study, Naismith JH, Baldwin AJ, Davis BG. Pathogen-sugar interactions revealed by universal saturation transfer analysis. *Science.* 2022 Jul 22;377(6604):eabm3125. doi: 10.1126/science.abm3125. Epub 2022 Jul 22. PMID: 35737812.

Deimel LP, **Sattentau QJ**. Shared sugars - parasite glycan homology in HIV-1 vaccine design. *Trends Parasitol.* 2022 Jul;38(7):498-500. doi: 10.1016/j.pt.2022.04.001. Epub 2022 Apr 29. PMID: 35501266.

Gartlan C, Tipton T, Salguero FJ, **Sattentau Q**, Gorringer A, Carroll MW. Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses. *Front Immunol.* 2022 Apr 4;13:882972. doi: 10.3389/fimmu.2022.882972. PMID: 35444667; PMCID: PMC9014240.

Patent Applications

Collaborative effort has resulted in a patent application that was filed 28th of April 2022 (European patent application No. 22386021.4 Erasmus University Medical Center Rotterdam and The University of Tokyo; Inventors: Peter D. Katsikis and Ken Ishii).

On-site Meetings

Name	Position, Institution	Total Days of Visits to IMSUT	Date of Visit
Peter Katsikis	Professor, Erasmus University	3	February 20 th 2023 February 21 st 2023 February 24 th 2023

On February 20th 2023, Professor Peter Katsikis visited IMSUT for scientific discussions between Professor Ken Ishii.

On February 21st 2023, Professor Peter Katsikis visited IMSUT for scientific discussions between Professor Ken Ishii, Dr. Kouji Kobiyama, Dr. Hideo Negishi, Dr. Burcu Temizoz and Dr. Tomoya Hayashi during a lunch meeting.

International Joint Usage/Research Center Seminar titled "Overcoming the obstacles for developing effective tumor neoantigen vaccines" was given by Professor Peter Katsikis on February 21st 2023 in IMSUT, Japan.

On February 24th 2023, Professor Peter Katsikis visited IMSUT for scientific discussions between Professor Ken Ishii and Dr. Burcu Temizoz.

Online Meetings

Throughout 2022 monthly 1½ hour joint online meeting were held between the Katsikis and Ishii laboratories. Postdoctoral fellows and students from both laboratories present their scientific research and share their latest findings while receive input and suggestions from both teams.

Name	Position, Institution	Date of the Online Meetings
Peter Katsikis	Professor, Erasmus University	February 15 th 2023
Ken Ishii	Professor, IMSUT	February 15 th 2023
Kouji Kobiyama	Assoc. Prof., IMSUT	February 15 th 2023
Burcu Temizoz	Assist. Prof., IMSUT	February 15 th 2023
Tomoya Hayashi	Postdoc, IMSUT	February 15 th 2023
Kou Hioki	Postdoc, Erasmus University	February 15 th 2023
Yvonne Mueller	Assist. Prof., Erasmus University	February 15 th 2023
Peter Katsikis	Professor, Erasmus University	December 5 th 2022
Ken Ishii	Professor, IMSUT	December 5 th 2022
Kouji Kobiyama	Assoc. Prof., IMSUT	December 5 th 2022
Burcu Temizoz	Assist. Prof., IMSUT	December 5 th 2022
Tomoya Hayashi	Postdoc, IMSUT	December 5 th 2022
Kou Hioki	Postdoc, Erasmus University	December 5 th 2022
Yvonne Mueller	Assist. Prof., Erasmus University	December 5 th 2022
Peter Katsikis	Professor, Erasmus University	November 7 th 2022
Ken Ishii	Professor, IMSUT	November 7 th 2022
Kouji Kobiyama	Assoc. Prof., IMSUT	November 7 th 2022
Burcu Temizoz	Assist. Prof., IMSUT	November 7 th 2022
Tomoya Hayashi	Postdoc, IMSUT	November 7 th 2022
Kou Hioki	Postdoc, Erasmus University	November 7 th 2022
Yvonne Mueller	Assist. Prof., Erasmus University	November 7 th 2022
Peter Katsikis	Professor, Erasmus University	October 7 th 2022
Ken Ishii	Professor, IMSUT	October 7 th 2022
Kouji Kobiyama	Assoc. Prof., IMSUT	October 7 th 2022
Burcu Temizoz	Assist. Prof., IMSUT	October 7 th 2022
Tomoya Hayashi	Postdoc, IMSUT	October 7 th 2022
Kou Hioki	Postdoc, Erasmus University	October 7 th 2022
Yvonne Mueller	Assist. Prof., Erasmus University	October 7 th 2022
Peter Katsikis	Professor, Erasmus University	September 5 th 2022
Ken Ishii	Professor, IMSUT	September 5 th 2022
Kouji Kobiyama	Assoc. Prof., IMSUT	September 5 th 2022
Burcu Temizoz	Assist. Prof., IMSUT	September 5 th 2022
Tomoya Hayashi	Postdoc, IMSUT	September 5 th 2022
Kou Hioki	Postdoc, Erasmus University	September 5 th 2022
Yvonne Mueller	Assist. Prof., Erasmus University	September 5 th 2022
Peter Katsikis	Professor, Erasmus University	August 10 th 2022
Ken Ishii	Professor, IMSUT	August 10 th 2022
Kouji Kobiyama	Assoc. Prof., IMSUT	August 10 th 2022

Burcu Temizoz	Assist. Prof., IMSUT	August 10 th 2022
Tomoya Hayashi	Postdoc, IMSUT	August 10 th 2022
Kou Hioki	Postdoc, Erasmus University	August 10 th 2022
Yvonne Mueller	Assist. Prof., Erasmus University	August 10 th 2022
Peter Katsikis	Professor, Erasmus University	July 13 th 2022
Ken Ishii	Professor, IMSUT	July 13 th 2022
Kouji Kobiyama	Assoc. Prof., IMSUT	July 13 th 2022
Burcu Temizoz	Assist. Prof., IMSUT	July 13 th 2022
Tomoya Hayashi	Postdoc, IMSUT	July 13 th 2022
Kou Hioki	Postdoc, Erasmus University	July 13 th 2022
Yvonne Mueller	Assist. Prof., Erasmus University	July 13 th 2022
Peter Katsikis	Professor, Erasmus University	June 1 st 2022
Ken Ishii	Professor, IMSUT	June 1 st 2022
Kouji Kobiyama	Assoc. Prof., IMSUT	June 1 st 2022
Burcu Temizoz	Assist. Prof., IMSUT	June 1 st 2022
Tomoya Hayashi	Postdoc, IMSUT	June 1 st 2022
Kou Hioki	Postdoc, Erasmus University	June 1 st 2022
Yvonne Mueller	Assist. Prof., Erasmus University	June 1 st 2022
Peter Katsikis	Professor, Erasmus University	May 10 th 2022
Ken Ishii	Professor, IMSUT	May 10 th 2022
Kouji Kobiyama	Assoc. Prof., IMSUT	May 10 th 2022
Burcu Temizoz	Assist. Prof., IMSUT	May 10 th 2022
Tomoya Hayashi	Postdoc, IMSUT	May 10 th 2022
Kou Hioki	Postdoc, Erasmus University	May 10 th 2022
Yvonne Mueller	Assist. Prof., Erasmus University	May 10 th 2022
Peter Katsikis	Professor, Erasmus University	April 6 th 2022
Ken Ishii	Professor, IMSUT	April 6 th 2022
Kouji Kobiyama	Assoc. Prof., IMSUT	April 6 th 2022
Burcu Temizoz	Assist. Prof., IMSUT	April 6 th 2022
Tomoya Hayashi	Postdoc, IMSUT	April 6 th 2022
Kou Hioki	Postdoc, Erasmus University	April 6 th 2022
Yvonne Mueller	Assist. Prof., Erasmus University	April 6 th 2022